Lewis Davis

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐬𝐢𝐭𝐞𝐬 𝐬𝐞𝐞𝐧 𝐚𝐬 𝐡𝐨𝐭 𝐩𝐫𝐨𝐩𝐞𝐫𝐭𝐲 𝐟𝐨𝐫 𝐏𝐄 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 Private equity is increasingly investing in clinical trial sites due to industry demand for larger networks, as shown by PitchBook's analysis of first quarter 2024 deal activity. Contract research organizations (CROs) are acquiring trial sites to enhance their service offerings, exemplified by American Clinical Research Services acquiring Elixia and Alcanza Clinical Research's focus on sites in Hispanic areas. This trend is part of a broader movement towards vertical and horizontal consolidation, aiming to create end-to-end drug development capabilities. #privateequity #clinicalresearchsites

4

🗞 Breaking news 🤩 Genezen acquire uniQure's commercial GT manufacturing ops in Lexington!! This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Check out full article below👇 #CDMO #Genezen #GeneTherapy

17

🔍 As the biotech industry evolves, professionals must adapt to changing job trends. Here are strategies to thrive in this shifting landscape: - Embrace Continuous Learning: Stay updated on the latest advancements to remain competitive. - Network Strategically: Build connections within the industry to explore new opportunities. - Leverage Transferable Skills: Highlight versatile skills applicable across various roles. - Seek Mentorship: Learn from experienced professionals to navigate career challenges effectively. - Embrace Flexibility: Be open to diverse roles and career paths within the biotech sector. - Stay Resilient: Develop a growth mindset to overcome setbacks and seize new opportunities. Let's discuss: How do you navigate career changes in the biotech industry? #BiotechCareer #ProfessionalDevelopment #IndustryInsights

2

🔬 Big News Alert! 🔬 🌟 FDA, EPA, and USDA join forces to streamline regulation for biotech products! 🌟 Interesting times ahead for the biotech industry as these agencies collaborate to simplify pathways to market while maintaining rigorous safety standards. How do you think this will shape the future of biotech? 💥 #Biotech #Regulation #Innovation #FDA #EPA #USDA

19

💊 Industry News Roundup 💊 🧠 Scientists, at Epoch Biotech, have discovered a new genetic clue for delaying Alzheimer's - this has been inspiring drug discovery and could be ground-breaking. 💲 Emergent BioSolutions sold their Baltimore facility for $30M to Bora Pharmaceuticals, which included 350 of Emergent's employees 🔥 Novo Nordisk office building in Denmark, set fire again. This is the third time in the last month - everyone was safe. ➕ Zealand Pharma hits early efficacy goal for amylin weight loss candidate - another movement in the obesity space 👀 😢 Cara Therapeutics have had to cut their workforce after trial failure 😍 iOnctura raises 80M to advance early-stage eye cancer treatment 👁 ❤️ Silence Therapeutics plc siRNA candidate for cardiovascular disease is continuing to deliver in Phase 2 trials!!! 💲 The target is set for new obesity biotech UroGen Pharma, aiming to raise over $107M 🐥 A tweet about a gene led a start-up called Marea raise $190M to develop a drug to lower a type of cholesterol, a new way of maybe attacking cardiovascular disease An exciting time in the biotech space, and if you haven't already - give our podcast The BioHub Podcast a follow.

11

1 Comment

Are you navigating the complexities of Clinical Operations in the Biotech sphere? The right talent is the linchpin of success, especially in the highly specialized and dynamic field of Clinical Operations. As a seasoned professional with a deep understanding of the Biotech industry, I've witnessed the transformative impact that strategic staffing solutions can bring to companies like yours. I offer bespoke contract staffing services tailored to the unique needs of Biotech firms across Europe. With a robust network of pre-vetted professionals and a keen eye for the perfect candidate-to-role match, my mission is to empower your operations with the agility and expertise required to thrive in today's market. Whether you're scaling up for a pivotal trial or need niche expertise to navigate regulatory landscapes, my approach is not just about filling a vacancy. It's about understanding your company's DNA and finding individuals who will accelerate your journey from research to real-world solutions. Let's collaborate to ensure your Clinical Operations are powered by the industry's best talent, giving you the competitive edge necessary to lead in innovation and patient outcomes. Ready to elevate your Clinical Ops with top-tier European talent? Let's talk! #BiotechTalent #ClinicalOperations #StaffingSolutions #Science #HRS

6

📢 US Lawmakers request FBI briefing on GenScript Biotech's China Links 🇺🇸🇨🇳 🚨 Update: The U.S. House Committee on China has asked the FBI and intelligence community for a briefing on GenScript Biotech and its subsidiaries, Bestzyme, Legend Biotech, and ProBio. Concerns revolve around potential Chinese Communist Party influence and risks to U.S. intellectual property. 🧬🔍 🔬 Key Points: GenScript Biotech: Major pharmaceutical research and manufacturing firm with a global presence. 🌍 Legend Biotech: Partnered with Johnson & Johnson on Carvykti, a cancer cell therapy with sales projected to exceed $5B annually. 💊💸 The committee worries about GenScript’s role in custom gene synthesis and its impact on U.S. biotech capabilities. 🧪🔐 📅 Legislative Context: This follows a bill aimed at reducing U.S. reliance on Chinese biotech firms. If passed, it could reshape the biotech landscape. 📜🛡️ 👥 Responses: GenScript asserts its independence and is open to cooperating with the House committee. 🏢🤝 Legend and J&J have yet to comment. #USChinaRelations #Biotech #Pharma #IntellectualProperty #Innovation #Healthcare #Legislation #GenScript #JohnsonAndJohnson #FBI

2

1 Comment

🚀 Opinion: Chinese CDMOs and US Biopharma PR strike a precarious balance 🌍 As the House Oversight and Accountability Committee marked up the BIOSECURE Act targeting China-based biotech companies like WuXi AppTec and WuXi Biologics, I couldn’t help but draw parallels to an epic Game of Thrones saga. 🐉🦅 In March 2024, WuXi AppTec separated from BIO after the industry trade association changed its stance to support the BIOSECURE Act. Recently, BIO proposed an eight-year decoupling period from China-based biomanufacturing, setting a 2032 deadline for U.S. biopharma companies to sever ties. 🕒⚖️ A floor vote is expected in the next 30 days, with WuXi Biologics intensifying their lobbying efforts. Nearly 20 biopharma and life sciences companies are also registered to lobby, striving to balance advocacy without appearing unpatriotic. 🤝💼 With almost 80% of U.S. biopharma companies linked to China-based CDMOs, this proposed grace period is critical to avoid disruptions. So, how can PR professionals navigate this complex landscape? 🌐🔍 Strategic Communication: Engage with industry associations like BIO to advocate for federal funding, similar to the CHIPS Act’s $200 billion support. 💬💰 Reassurance Through Transparency: CDMOs should prioritize international communications, highlighting their commitment to global markets and high regulatory standards. 📢🌍 Proactive Outreach: Use third-party audits, certifications, and data points to assuage client concerns. Focus on professional platforms like industry publications and LinkedIn. 📄✅ As Lord Varys from Game of Thrones noted, “A small man can cast a large shadow.” Thoughtful, strategic actions can influence outcomes and ensure sustainable growth for the U.S. biopharma industry and China-based CDMOs. 🌟 #Biopharma #PR #BIOSECUREAct #WuXiAppTec #WuXiBiologics #USChinaRelations #CDMO #Biotech #Pharmaceuticals #Legislation #Healthcare #GlobalBusiness #StrategicCommunication

1

1 Comment

🌟 Breaking News: Touchlight, CGT Catapult, and Complement Therapeutics Join Forces! 🌟 🚀 Innovative Manufacturing Process for Gene Therapies 🚀 I'm excited to share some groundbreaking news in the biotech industry. Touchlight, Cell and Gene Therapy Catapult (CGT Catapult), and Complement Therapeutics have partnered to develop an advanced manufacturing process for gene therapies. This collaboration has been awarded over £1 million by Innovate UK and aims to revolutionise the production of recombinant adeno-associated virus (rAAV) gene therapies. 📅 Key Highlights: Grant Award: Over £1 million from Innovate UK Objective: Develop innovative rAAV production process using dbDNA™ Collaborators: Touchlight, CGT Catapult, and Complement Therapeutics 🔬 Project Details: Touchlight's enzyme-based DNA manufacturing platform will produce doggybone DNA (dbDNA™), which is significantly faster to produce than traditional plasmid DNA. This innovation aims to increase yield, lower costs, and reduce the environmental impact of manufacturing gene therapies. The dbDNA will be used to produce rAAV, which will then be utilized to manufacture Complement Therapeutics' gene therapy candidates. CGT Catapult will optimize its rAAV manufacturing and analytical platform to support this process, ultimately helping gene therapy developers across the UK. 🗣️ Statements from Leaders: Karen Fallen, CEO, Touchlight: "We are excited to combine our dbDNA technology with those of Complement Therapeutics and CGT Catapult to develop an innovative solution to AAV production. dbDNA has the potential to improve the productivity and thus, the cost of AAV manufacture, while also eliminating bacterial impurities." Rafiq Hasan, CEO, Complement Therapeutics: "We are looking forward to this collaboration in exploring the potential of this innovative dbDNA technology in the manufacture of our AAV gene therapy candidates." Matthew Durdy, CEO, CGT Catapult: "Building on Touchlight’s pioneering dbDNA platform and Complement Therapeutics’ expertise in gene therapies, we hope to develop an innovative process that streamlines viral vector manufacturing and helps to reduce the cost of advanced therapies." 🌍 Impact: This collaboration has the potential to make life-changing gene therapies more affordable and accessible by improving manufacturing processes, increasing yield, and lowering costs. #GeneTherapy #Biotechnology #InnovateUK #Touchlight #CGTCatapult #ComplementTherapeutics #dbDNA #rAAV #HealthcareInnovation #AdvancedTherapies #Biotech #MedicalResearch #LifeSciences

6

1 Comment

One for my Diagnostic network - I'm interested to hear thoughts on the FDA's plan to bring LDTs into its regulatory fold over the next 4 years? What impact is this going to have on the market? 👇 ✏ #FDA #IVD #diagnostics #LDTs #labdevelopedtests #IVDS

2

🌍 Bio & ASCO are just around the corner! 📢 They are some of the largest and most influential global events in the biotechnology industry. These conferences bring together a wide array of professionals from the biotech, pharmaceutical, and related sectors. 👨‍🔬 These conferences will feature over 100 educational sessions, 250 spoken presentations, 16 clinical science symposia, 24 abstract sessions, and more than 2,000 poster presentations. 🧬 As a head-hunter in the life sciences industry, these conferences are a prime venue and perfect opportunity to connect companies with prospective candidates. I can schedule informal meetings to discuss market trends and hiring strategies, explore a diverse talent pool, and identify top candidates who can drive innovation and growth in your organization. 🙋‍♂️ Are you attending one of the conferences this year? #ASCO2024 #BIO #Conferences #Networking #Biotech #Oncology

9

🔬 Attention U.S. Biotech and Pharma Professionals: Major Industry Shifts on the Horizon? 🧪 The ongoing scrutiny of Chinese CDMOs, particularly WuXi AppTec, could reshape our industry landscape. Here's what you need to know: 1. The BIOSECURE Act, if passed, could force U.S. drugmakers to cut ties with certain Chinese biotech companies by 2032. This affects over 120 U.S. biopharma drugs currently partnered with these firms. 2. WuXi AppTec's deep integration in U.S. pharma (involved in developing ~25% of drugs used in the U.S.) means any restrictions could have far-reaching effects on drug development pipelines. 3. Indian CDMOs are positioning themselves to potentially fill the gap. With a market estimated at $22 billion and growing, they're ramping up investments in capacity and capabilities. 4. However, challenges remain. Indian CDMOs may face hurdles in small molecule production and need to address quality concerns. 5. We might see a push towards domestic U.S. CDMOs as concerns grow about offshore dependencies. As industry professionals, we need to stay ahead of these potential shifts. How is your organization preparing for possible changes in the CDMO landscape? #Biotech #Pharma #CDMO #DrugDevelopment #RegulatoryChanges

6

📈 Biopharma's Q1 2024 Earnings: Winners & Losers 📉 The first quarter of 2024 showcased significant trends in the biopharma industry, with some companies soaring while others faced challenges. Here's a roundup of the winners and losers based on Q1 results! 💼💰 Winners: 🥇 Amgen: Reported solid Q1 financial results, with total revenues of $7.4 billion, driven by product sales growth of 22%. The integration of sales from Horizon' acquisition contributed significantly. 🥈 AstraZeneca: Total revenue surged by 19% to $12.6 billion, fuelled by strong performance in oncology and cardiovascular divisions, especially in emerging markets. 🥉 Novo Nordisk: Posted a 27% increase in operating profit, driven by robust sales in diabetes and obesity care, particularly with GLP-1 products Ozempic and Wegovy. Despite growth, Novo Nordisk's share price dropped by 3%, possibly due to cautious guidance updates. Losers: 👎 Biogen: Faced challenges with declining revenue, particularly in multiple sclerosis products, resulting in a 6.9% YoY drop. The company's transition period includes the redesign of its portfolio and reliance on Leqembi for future revenue. 👎 Bristol Myers Squibb: Despite revenue growth, downgraded EPS guidance and announced layoffs, causing a nearly 8% drop in share price. Patent cliffs and recent acquisitions impact future outlook. 👎 Johnson & Johnson: Missed analyst estimates, with sales growth falling short. Stelara's biosimilar competition adds pressure, despite better-than-expected income. The Q1 earnings season provides valuable insights into the biopharma landscape, showcasing both successes and challenges. Stay tuned for more updates in the industry! 🌐💡 #Biopharma #EarningsSeason #WinnersAndLosers #Healthcare #Finance #BusinessInsights #Pharmaceuticals #Investing #StockMarket #Innovation #Challenges #Opportunities 📊🔬💼

4

1 Comment

Seeking Biotech Pioneers! In the fast-paced world of biotechnology, the right team isn't just an asset; it's the heartbeat of innovation. As a seasoned professional in the Clinical Operations sector, I understand the unique challenges you face in staffing projects that push the boundaries of science and medicine. Are you tirelessly searching for that perfect fit to drive your clinical trials forward? Look no further. My expertise lies in providing bespoke contract staffing solutions tailored to the dynamic needs of biotech firms across Europe. I bridge the gap between visionary companies and the top-tier talent they need to thrive. Here's what I bring to your table: - A robust network of pre-vetted clinical operations professionals - Swift turnaround times to keep your projects on track - A deep understanding of the biotech landscape and regulatory requirements - Flexible staffing models to suit your project scale and duration Whether you're a start-up on the verge of a breakthrough or an established firm scaling new heights, my goal is to empower your mission with the right people behind the science. Let's collaborate to build a future where health innovations reach those who need them most, faster and more efficiently. Drop a comment, send a message, or simply hit 'Like' if you're ready to elevate your clinical operations with the top talent in the industry. #BiotechTalent #ClinicalOperations #StaffingSolutions #Science #HRS

6

🗨️ Trends shaping the CDMO Landscape in 2024 - Interview with Gil Roth Roth, PBOA - Pharma & Biopharma Outsourcing Association PharmaSource spoke with Gil Roth to get his take on the challenges and opportunities faced by the CDMO sector, including: 👉 Headline M&A deals 👉 Impact of the BIOSECURE and Inflation Reduction Acts 👉 The upcoming election And much more... Listen below ⬇️🎧 #CDMO #ContractManufacturing #ContractDevelopment

19

2 Comments

🔔 The End of eFFECTOR Therapeutics, Inc.: Oncology Biotech Winds Down After Mid-Stage Fail 🔔 It’s a somber day in the biotech world as eFFECTOR Therapeutics announces its closure. The oncology-focused biotech is winding down operations after a mid-stage trial setback. 📉 Key Updates: -Layoffs Announced: CEO Stephen Worland, Ph.D., CFO Michael Byrnes, and CMO Douglas Warner, M.D., have all stepped down. -New Leadership: Craig Jalbert from Verdolino & Lowey, P.C. has been appointed as the new CEO, president, treasurer, secretary, and sole board member. -Financial Impact: Expected one-time charges and cash expenditures of about $600,000 by June 30. -Strategic Alternatives: The company is exploring options for its development programs, including its lead asset, zotatifin. -Failed Trials: Tomivosertib, a key asset, failed to improve progression-free survival in a phase 2b trial for NSCLC. -Partnerships: Previous partnership with Pfizer for preclinical asset eIF4Ei, which aimed to tackle solid tumors. -Stock Plummet: Since the announcement, eFFECTOR’s stock dropped 77% from $1.17 per share to 29 cents. Founded in 2012, eFFECTOR Therapeutics was built on groundbreaking research from UCSF. Despite this setback, the pursuit of innovation in oncology continues. 💡🔬 #Biotech #Oncology #ClinicalTrials #Pharma #Healthcare #Biopharma #Research #Innovation #LeadershipChange #Pharmaceuticals #eFFECTORTherapeutics #CancerResearch #DrugDevelopment #BiotechNews #HealthTech #Nasdaq #StrategicAlternatives #HealthcareIndustry #BiotechCommunity 4o

2

1 Comment

🚀 Vertex Pharmaceuticals (VRTX) is Trending! 🌟 Vertex Pharmaceuticals (VRTX) is making waves in the biotech sector, capturing the attention of investors and industry experts alike. 🌐 🔍 Key Highlights: -Strong Market Performance: Vertex continues to show robust market trends, driven by its innovative approach and strategic focus on transformative medicines. -Innovative Pipeline: The company’s dedication to developing cutting-edge treatments for serious diseases keeps it at the forefront of biotech innovation. -Financial Strength: Vertex's solid financial health and consistent revenue growth reflect its effective business strategies and market adaptability. -Vertex's commitment to advancing healthcare through groundbreaking research and development is truly inspiring. Their focus on delivering high-impact therapies underscores their leadership in the biotech industry. 🌟 Let's celebrate Vertex's achievements and anticipate more groundbreaking developments ahead! #VertexPharmaceuticals #VRTX #BiotechInnovation #HealthcareLeadership #MarketTrends #InvestmentNews #CuttingEdgeResearch #TransformativeMedicines #FinancialGrowth #InvestorUpdate

2

1 Comment

Every time I think things are on the rebound I see something like this. When are things finally going to stabilize and head in the right direction? If there is anyone that may be affected by this, let's connect and have a discussion about your career. #career #discussion #connect

14

1 Comment